Corporate ActionJul 17, 2026, 04:51 PM
Glucotrack to Vote on Reverse Stock Split, Warrant Inducement at AGM
AI Summary
Glucotrack, Inc. announced its Annual Meeting of Stockholders to be held on August 18, 2026, where shareholders will vote on several key proposals. These include the election of six directors, an advisory vote on executive compensation, and the ratification of the independent auditor. Significantly, the company recently completed a merger with Lokahi Therapeutics, Inc., resulting in Erik Emerson's appointment as CEO and Paul V. Goode's transition to Chief Technology Officer. Shareholders will also vote on approving a reverse stock split at a ratio not exceeding one-for-thirty and a warrant inducement plan for Nasdaq compliance.
Key Highlights
- Glucotrack's Annual Meeting of Stockholders is scheduled for August 18, 2026.
- Shareholders will vote on the election of six directors and an advisory vote on 2025 executive compensation.
- A merger with Lokahi Therapeutics, Inc. was completed on July 14, 2026, with Lokahi becoming a wholly-owned subsidiary.
- Erik Emerson was appointed Chief Executive Officer and Director in July 2026 following the merger.
- Paul V. Goode transitioned from CEO to Chief Technology Officer in July 2026.
- Shareholders will vote on approving a reverse stock split at an aggregate ratio not to exceed one-for-thirty.
- Approval is sought for a warrant inducement plan to reprice existing warrants and issue new ones for Nasdaq compliance.
- CBIZ CPAs P.C. is proposed for ratification as the independent registered public accounting firm for 2026.
Price Impact
More from GCTK